Company Bould Opportunities PLC

Equities

PSL

GB00B1TK2453

Construction Supplies & Fixtures

Delayed London S.E. 02:30:01 2019-10-07 am EDT 5-day change 1st Jan Change
0.023 GBX -.--% Intraday chart for Bould Opportunities PLC +24.32% +43.75%

Business Summary

Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 396,391,773 278,493,918 ( 70.26 %) 0 70.26 %

Shareholders

NameEquities%Valuation
31,333,857 8.612 % 732 272 p
14,858,844 4.084 % 347 251 p
Unicorn Asset Management Ltd.
0.009400 %
34,200 0.009400 % 799 p
CFS Management Ltd.
0.002892 %
10,521 0.002892 % 246 p
Downing Ventures
0.002019 %
7,346 0.002019 % 172 p
Rathbones Asset Management Ltd.
0.000443 %
1,612 0.000443 % 38 p
Amati Global Investors Ltd.
0.000212 %
772 0.000212 % 18 p
Swedbank Robur Fonder AB
0.000190 %
692 0.000190 % 16 p
FIL Gestion SASU
0.000034 %
124 0.000034 % 3 p
King & Shaxson Asset Management Ltd.
0.000007 %
26 0.000007 % 1 p

Company contact information

Cizzle Biotechnology Holdings Plc

60 Gracechurch Street 6th Floor

EC3V 0HR, London

+44 20 7469 0930

http://www.cizzlebiotechnology.com
address Bould Opportunities PLC(PSL)
  1. Stock Market
  2. Equities
  3. PSL Stock
  4. Company Bould Opportunities PLC